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Abstract 
In Europe, the compound 3,4-methylenedioxymethamphetamine 
(MDMA, Ecstasy, Adam), in addition to cannabis, is the most 
abused illicit drug at all-night "techno" parties. Methods for the 
determination of MDMA and its metabolites, 4-hydroxy-3- 
methoxymethamphetamine (HMMA), 3,4-dihydroxy- 
methamphetamine (HHMA), 3,4-methylenedioxyamphetamine 
'~4nA), 4-hydroxy-3-methoxyamphetamine (HMA), and 
3,4-dihydroxyamphetamine (HHA), in biological fluids were 
established. Plasma and urine samples were collected from two 
patients in a controlled clinical study over periods of 9 and 22 h, 
respectively. MDMA and MDA were determined in plasma and 
urine by reversed-phase high-performance liquid chromatography 
with diode array detection (HPLC-DAD) after solid-phase 
extraction on cation-exchange columns. Acidic or enzymatic 
hydrolysis was necessary to detect HMMA, HMA, HHMA, and 
HHA, which are mainly excreted as glucuronides. Gas 
chromatography-mass spectrometry (GC-MS) was used for 
confirmation. Sample extraction and on-disc derivatization with 
heptafluorobutyric anhydride (HFBA) were performed on Toxi-Lab 
SPEC solid-phase extraction concentrators. After administration of 
a single oral dose of 1.5 mg/kg body weight MDMA, peak plasma 
levels of 331 ng/mL MDMA and 15 ng/m/MDA were measured 
after 2 h and 6.3 h, respectively. Peak concentrations of 
28.1 pg/m/MDMA in urine appeared after 21.5 h. Up to 
2.3 pg/mL MDA, 35.1 pg/mL HMMA, and 2.1 pg/mL HMA were 
measured within 16-21.5 h. Conjugated HMMA and HHMA are 
the main urinary metabolites of MDMA. 
Introduction 
The recreational use of 3,4-methylenedioxymethylamphet- 
amine (MDMA; Figure 1) dramatically increased in the United 
States and Europe by the mid to late 1980s. In Britain, more 
than 500,000 people are said to use the drug each week (1). 
Since 1986, MDMA has been an internationally controlled sub- 
"Author to whom correspondence should be addressed. 
stance. It shows distinct psychotropic effects, which are dif- 
ferent from those of the structurally related stimulant amphet- 
amine or hallucinogenic phenylalkylamines (e.g., 3,4-methyl- 
enedioxyamphetamine [MDA] and 3,4,5-trimethoxyphenethyl- 
amine [mescaline]) (2-6). MDMA is reported to possess 
antidepressant and anxiolytic properties and to evoke a con- 
trollable emotional experience with relaxation, peaceful feel- 
ings, increased empathy, and a drop in fear responses that are 
mostly without distortion of sensory perception and thought 
and without marked stimulation (5-10). A novel psychoactive 
substance class, which is named the "entactogens" (greco- 
latinic term: "produce (gen) an inner Ien) touching (tact)") was 
recently proposed for MDMA (3,5-7,11). The mechanism of 
action of MDMA is characterized by a high affinity at sero- 
tonin uptake sites, whereas at norepinephrine and dopamine 
uptake sites of central neurons the affinity is lower (12). 
Reviews of the pharmacology of MI)MA have appeared in the 
literature (13,14). 
The acute and chronic toxicity of MDMA is controversial. In 
animal experiments MDMA was shown to exert dose- and 
species-dependent neurotoxic effects on central serotonergic 
neurons in terms of degeneration of axon terminals (12,15-22). 
However, the relevance of these findings for humans is still 
unclear (23-25). There are no reports of individuals or drug- 
addicts who take frequent or large doses of MDMA for extended 
periods of time. The reason for this is that the positive effects 
of the drug seem to diminish and the negative effects seem to 
increase with time (5,8). Well-documented deaths related to the 
use of MDMA are exceptionally rare and are mostly the result 
of underlying cardiac diseases, cardiovascular complications, 
and hyperthermia (26-28}. A recent postmortem study on 
seven men (age range 20-25) who died after the consumption 
of MDMA ("Ecstasy") or 3,4-methylenedioxyethylamphetamine 
(MDEA, "Eve") or both showed significant changes in the liver, 
heart, or brain (1). As the possible mechanism of damage, the 
authors suggested hyperthermia, direct toxic effects on or- 
gans, individual susceptibility to ring substituted am- 
phetamines, abnormal metabolism, and water intoxication. 
On the other hand, there is also an ongoing discussion about 
the therapeutic potency of MDMA. For example, MDMA is used 
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in medicine as an adjunct in psychotherapy (5,7,9,29,30), 
where it can facilitate the therapeutic communication and 
increase patient insight and self-esteem (26), and as an 
analgesic for patients with terminal cancer (31). 
High-performance liquid chromatography (HPLC) with elec- 
trochemical (32,33), UV (34), or diode array detection (DAD) 
(35) and gas chromatography with nitrogen-phosphorus de- 
tection (GC-NPD) (36) or mass spectrometry (GC-MS, 
GC-MS-MS, GC-MS-MS-MS) (32,37-44) have been used for 
the detection of MDMA in biological specimens. 
Several animal studies (rat and mouse) have shown that 
MDMA is metabolized by N-demethylation, Oodealkylation, 
deamination, O-methylation, and O-conjugation to glucuronides 
and/or sulfates. Metabolites detected in urine are 3,4-methylene- 
dioxyamphetamine (Figure 1, MDA), 4-hydroxy-3-methoxy- 
methamphetamine (HMMA), 3-hydroxy-4-methoxymeth- 
amphetamine, 4-hydroxy-3-methoxyamphetamine (HMA), 
3-hydroxy-4-methoxyamphetamine, 4-hydroxy-3-methoxy- 
phenylacetone, 3,4-methylenedioxyphenylacetone, and 3,4- 
dihydroxyphenylacetone (32,36,37,41,42). Most of these metabo- 
lites are also present in the blood. In addition, 6-hydroxy- 
3,4-methylenedioxymethamphetamine and 6-hydroxy-3,4- 
methylenedioxyamphetamine have been found in rat plasma 
and brain (39), whereas 2,4,5-trihydroxymethamphetamine 
and 2,4,5-trihydroxyamphetamine have been identified in rat 
liver (40). 
Very few MDMA studies have been performed in man. In a 
postmortem urine specimen (with unknown dosage), HMMA 
was detected as the main urinary metabolite of MDMA. Other 
metabolites found were MDA, HMA, 3,4-dihydroxymetham- 
phetamine (HHMA), 3-hydroxy-4-methoxymethamphetamine, 
and 3,4-methylenedioxyphenylacetone (38). In a single patient, 
controlled study, unchanged MDMA was the major urinary 
excretion product, and MDA was the only metabolite identified 
after the ingestion of 50 mg MDMA. Of the dosage given, 72% 
was recovered from the urine within 72 h. The MDMA plasma 
level peaked at about 106 ng/mL 2 h after administration and 
declined to about 5 ng/mL by 24 h (43). 
It was the aim of the present study to establish the analytical 
methodology for monitoring MDMA and its metabolites in 
body fluids and to investigate the pharmacokinetic behavior of 
MDMA in man under controlled conditions. 
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Experimental 
Standards and chemicals 
(• hydrochloride 
(MDMA) was purchased from Eprova (Schaffhausen, Switzer- 
land); (• hydrochloride 
(MDA) and (+)-methamphetamine hydrochloride (MA) were 
obtained from Sigma (Buchs, Switzerland). (• 
methoxymethamphetamine (HMMA) was synthesized by 
reaction of methylamine hydrochloride, sodium cyanoboro- 
hydride, and 4-hydroxy-3-methoxyphenylacetone, which was 
prepared by the oxidation of 4-hydroxy-3-methoxyphenyl-2- 
nitropropene (45). (• 
(HMA) was synthesized by the reduction of 4-hydroxy-3- 
methoxyphenyl-2-nitropropene, which was prepared by reac- 
tion of 4-hydroxy-3-methoxybenzaldehyde with nitroethane 
(45). (• (HHMA) was syn- 
thesized by demethylation of 3,4-dimethoxymethamphetamine 
with borotribromide (46). 3,4-Dimethoxymethamphetamine 
was prepared by reacting 3,4-dimethoxyphenylacetone, methyl- 
amine hydrochloride, and sodium cyanoborohydride (45). 
(• (HHA) was synthesized by 
reaction of 3,4-dibenzoylbenzaldehyde with nitroethane to yield 
3,4-dibenzoylphenyl-2-nitropropene, followed by reduction to 
3,4-dibenzoylamphetamine and debenzylation to HHA (47). All 
synthesized standards were prepared as hydrochlorides, and 
the structures were confirmed by MS, infrared spectroscopy 
(IR), proton (1H-), and carbon nuclear magnetic resonance 
spectroscopy (13C-NMR). [3-Glucuronidase/sulfatase type H-1 
was purchased from Sigma. All other chemicals and reagents 
were of HPLC or analytical grade and were purchased from 
Merck (Zurich, Switzerland) or Fluka (Buchs, Switzerland). 
Sample collection and preparation 
Plasma and urine samples. The plasma and urine speci- 
mens were obtained from a female (40-year-old subject A) and 
a male patient (23-year-old subject B) treated with MDMA by a 
psychiatrist (J.S., one of the authors) from The Swiss Associa- 
tion for Psycholytic Therapy (SAPT) under 
the authorization of the Swiss Federal Office 30 
of Public Health. Blood samples (10-20 mL 
each) were obtained through an indwelling 
catheter at 0, 15, 30, 45, 60, 75, 90, 105, 20 
120, 135, 150, 170, 190, 220, 250, 310, 380, 
450, and 530 rain after the oral administra- 
tion of 1.5 mg MDMA (calculated as base) c lO 
per kg body-weight. The heparinized blood 
samples were centrifuged for 10 rain at 
2000 rpm; the plasma was transferred to 
polypropylene tubes and stored at -20~ o 
Urine samples from subject A were collected 
0, 1.5, 3.5, 5.5, 7.5, 10, 22, and 23.75 h after 
the administration of MDMA, and urine 
samples from subject B were collected 0, 1, 
1.25, 1.5, 3.75, 4.2, 5, 5.5, 6.4, 8.4, 10.5, 12.5, 
16, and 21.5 h after the administration of 
MDMA. The samples were stored at -20~ 
Preparation of plasma extracts for HPLC. The solid-phase 
extraction (SPE) and cleanup of plasma samples were per- 
formed on an automated SPE system (ASPEC, Gilson Medical 
Electronics France S.A., Synmedic, Zurich, Switzerland). 
Frozen plasma samples were warmed up to room tempera- 
ture in an ultrasonic bath and centrifuged, if necessary. To an 
aliquot of 1.2 mL plasma 100 pL of the internal standard 
solution (800 ng/mL MA in water) and 0.6 mL 75 mM H3PO4 
(85%) were added, sonicated for 1 rain in a stoppered 2.5-mL 
vial, and centrifuged for 10 min at 2000 rpm. The supernatant 
(1.5 mL) was then applied to the Adsorbex SCX (100 mg) 
cation-exchange SPE column (Merck, Zurich, Switzerland), 
which was preconditioned with 2 mL methanol, 1 mL water, 
and 2 mL 25mM KH2PO4. After drying the column with 6 mL 
of air, plasma interferences were removed by washing with 
1.5 mL of 25mM KH2PO4 and 1 mL of methanol, followed by 
1.6 mL of air. The elution was done twice with 1.25 mL of 
methanol-HCl 7.3% (97.5:2.5), followed by 1 mL of air. After 
addition of 90 pL of 1M K2HPO4 to a 2-mL aliquot of the eluate, 
the solution was concentrated to about 100 IJL under a stream 
of nitrogen and reconstituted to exactly 200 IlL with water. 
After filtration through the tip of a Pasteur pipette filled with 
cotton wool, 25 pL of the filtrated solution was used for HPLC. 
Preparation of urine extracts for HPLC. SPE and cleanup of 
urine samples were carried out according to the procedure 
described earlier (35), but modified for the use on the ASPEC 
system. Frozen urine samples were warmed up to room tem- 
perature in an ultrasonic bath and centrifuged if necessary. To 
an aliquot of 1.4 mL urine 14 ]aL of the internal standard 
solution (1.24 mg/mL MA in water) and 0.6 mL 75 mM KH2PO4 
were added. The pH was adjusted to 5 with 200 mM H3PO 4 
when necessary and sonicated for 1 rain in a stoppered 2.5-mL 
vial. An aliquot (1.5 mL) of this sample was then applied to the 
Adsorbex SCX (100 rag) cation-exchange SPE column, which 
was preconditioned with 2 mL methanol, 1 mL water, and 1 mL 
25 mM KH2PO4. After drying the column with 6 mL of air, 
urine interferences were removed by washing with 1.5 mL of 
25 mM KH2PO4 and 1 mL of methanol, followed by 1.6 mL of 
I 
t 
2 3 
0 2 4 B 8 10 
Time (min) 
Figure 2. HPLC profile of a plasma extract; subject B, 120 min after an oral dose of 1.5 mg/kg 3,4- 
methylenedioxymethamphetamine (MDMA). Peaks: 1, 3,4-methylenedioxyamphetamine (MDA, 3.9 
ng/mL); 2, methamphetamine (MA, internal standard); 3, 3,4-methylenedioxymethamphetamine 
(MDMA, 331.3 ng/mL). 
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air. The elution was done twice with 1 mL methanol-HC1 7.3% 
(97.5:2.5), followed by 1 mL of air. After the addition of 68 pL 
1M K2HPO4 to a 1.5-mL aliquot of the eluate, the solution was 
concentrated to about 100 pL under a stream of nitrogen and 
reconstituted to exactly 150 laL with water. After filtration 
through the tip of a Pasteur pipette filled with cotton wool, 
3 pL of the filtrated solution was used for HPLC. 
Enzymatic hydrolysis. For the enzymatic hydrolysis of the 
conjugates, 0.6 mL 75 mM KH2PO4, containing 10000 units/mL 
urine of ~-glucuronidase/sulfatase (from Helix pomatia, type 
H-l) was added to 1.4 mL of urine with 14 pL internal standard 
solution. The mixture was then incubated for 16 h at 37~ 
After centrifugation, 1.5 mL of the supernatant solution was 
extracted as described previously, and a 3-1aL aliquot of the 
filtrated extract was used for HPLC. 
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Acidic hydrolysis. HCI (0.4 mL; 37%) was added to 2 mL of 
urine with 20 pL internal standard solution, and the mixture 
was incubated for 15 min at 120~ and 105 Pa pressure. After 
cooling to room temperature, the mixture was centrifuged 
(2000 rpm for 5 min), and 1.5 mL of the supernatant solution 
was applied to the Bakerbond C-18 (300 mg) SPE column (P.H. 
Stehelin & Co., Basel, Switzerland). The column was precon- 
ditioned with 3 mL methanol and 6 mL water. Urine interfer- 
ences and the excessive hydrochloric acid were removed by 
washing with 6 mL water. After drying the column with 6 mL 
of air, the elution was done with 1.5 mL of methanol- 
75mM KH2PO4 (95:5) followed by 5 mL of air. The methanol 
was evaporated to 50 pL under a stream of nitrogen and 
reconstituted to 1.75 mL with 50 mM KH2PO4. An aliquot of 
1.5 mL was extracted on the Adsorbex SCX (100 mg) cation- 
exchange SPE column as described previ- 
A ously. After the addition of 68 laL of 1M 
6 K2HPO4, the eluate was concentrated to 
200 IlL, and a 3-pL aliquot of the filtrated 
extract was used for HPLC. 
Preparation of urine extracts for GC-MS. 
Extraction and cleanup of urine specimens 
and the preparation of HFBA derivatives by 
On-Disc Derivatization TM (ODD) with hep- 
tafluorobutyric anhydride were performed 
by using TOXI-LAB | SPEC VC MP1 (15 rag) 
microcolumns (Toxi-Lab, Irvine, CA; Spec- 
tronex AG, Basel, Switzerland) and fol- 
B lowing the instructions of the manufacturer 
for the extraction of amphetamine and 
methamphetamine. After derivatization, 
200 IlL water was added to the hexane- 
HFBA mixture and strongly shaken. The 
water phase was discarded, and 200 IlL of 
4% NH4OH was added. The mixture was 
shaken again. A l-IlL aliquot of the hexane 
layer was used for GC-MS analysis. The 
enzymatic and acidic hydrolysis were done 
as described for HPLC analysis. 
5 
5 
0 
13me (min) 
C 
Figure 3. HPLC profiles of an urine extract before (A) and after enzymatic (B) or acidic (C) hydrolysis; 
subject B, 21.5 h after an oral dose of 1.5 mg/kg 3,4-methylenedioxymethamphetamine. Peak iden- 
tification: 1,3A-dihydroxymethamphetamine (HHMA); 2, 4-hydroxy-3-methoxyamphetamine (HMA, 
2.1 pg/mL, after acidic hydrolysis); 3, 4-hydroxy-3-methoxymethamphetamine (HMMA, 31.3 pg/mL); 
4, 3,4-methylenedioxyamphetamine (MDA) (1.6 pg/mL); 5, methamphetamine (MA, internal standard); 
6, 3,4-methylenedioxymethamphetamine (MDMA, 18.1 pg/mL). 
HPLC analysis 
The HPLC system consisted of a Hewlett- 
Packard (HP) (Waldbronn, Germany) 
1090M liquid chromatograph with an HP 
1040M DAD and an HP HPLC 3D Chem- 
station (software version A.02.00). The 
separation of plasma and urine samples 
was performed isocratically at 40~ on a 
150 x 4.6-mm internal diameter column 
with a 20 • 4.0-mm internal diameter 
precolumn packed with 3-1am Spherisorb 
ODS-1. The mobile phase was acetoni- 
trile-water (96:904, v/v) containing 5.0 mL 
(8.5 g) orthophosphoric acid (85%) and 
0.28 mL (0.22 g) hexylamine per 1000 mL. 
The flow rate was 1 mL/min. The quantita- 
tion of MDMA, MDA, HMMA, and HMA 
before and after enzymatic or acidic 
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hydrolysis was performed at 200 nm by measuring the peak 
areas and using the internal standard method. 
GC-MS analysis 
The GC-MS system consisted of a HP 5990 GC with a HP 
5970 mass selective detector (MSD). A 1-pL aliquot of the 
derivatized urine extracts was separated on a J&W Scientific 
(HSP Friedlid Co., K6niz, Switzerland) DB-5 bonded-phase 
capillary column (20 m x 0.18-ram i.d.; 0.40-pm film thick- 
ness) directly inserted into the ion source. The injector and 
transfer line temperatures were 260 and 280~ respectively. 
The oven temperature was programmed from 70~ (held 
1 rain) to 200~ at 10~ and from 200~ (held I min) to 
280~ (held 14 rain) at 15~ Helium was used as the car- 
rier gas at a flow rate of 0.7 mL/min. The MS was operated in 
the scan and the SIM mode. The scan range was m/z 33-780, 
and the scan-rate was set at 0.57 scans/sec. The characteristic 
ions were m/z 389, 254, 210, 162, 135 (MDMA-HFBA); 375, 
240, 162, 135 (MDA-HFBA); 587, 360, 254, 210 (HMMA-di- 
HFBA); 573, 360, 240, 163 (HMA-di-HFBA); 769, 542, 515, 
254, 210 (HHMA-tri-HFBA); and 755, 542, 515,240, 210 (HHA- 
tri-HFBA). 
Results and Discussion 
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Figure 4. GC-MS full scan profile of a derivatized urine extract before (A) and after enzymatic (B) and 
acidic (C) hydrolysis; subject B, 21.5 h after an oral dose of 1.5 mg/kg 3,4-methylenedioxymetham- 
phetamine (MDMA). Peak identification: 1, methamphetamine (MA, internal standard); 2, 3,4-dihy- 
droxyamphetamine (HHA); 3, 3,4-methylenedioxyamphetamine (MDA); 4, 4-hydroxy-3-methoxy- 
amphetamine (HMA); 5, 3,4-dihydroxymethamphetamine (HHMA); 6, 4-hydroxy-3- 
methoxymethamphetamine (HMMA); 7, 3,4-methylenedioxymethamphetamine (MDMA). 
HPLC analysis 
The same SPE procedure, which can be 
automated for serial analysis, has been used 
for the preparation of plasma and urine 
samples for HPLC analysis. As shown by 
Figures 2 and 3, most of the endogenous 
matrix is eliminated by the highly selective 
cation-exchange column, whereas about 98 
and 99% of MDMA is recovered from plasma 
and urine, respectively. The recovery of 
MDMA was determined using two plasma 
samples spiked with 49 and 493 ng/mL 
MDMA and two urine samples spiked with 
1800 and 8800 ng/mL MDMA. The extrac- 
tion efficiency for the MDMA metabolites 
(MDA, HMMA, HMA) was determined to be 
good to excellent. Urine samples were 
spiked with 400 ng and 800 ng/mL MDA, 
725 and 7250 ng/mL HMMA, and 800 and 
4000 ng/mL HMA. The recoveries were 100, 
90, and 68% for MDA, HMMA, and HMA, 
respectively. Methamphetamine (MA) was 
chosen as the internal standard for plasma 
and urine. Amphetamine was too polar and 
interfered with the biological matrix. 
For the determination of the conjugated 
mono- and dihydroxylated MDMA metabo- 
lites (HMMA, HMA, HHMA, etc.) enzymatic 
or acidic hydrolysis was necessary prior to 
SPE. The hydrolysis with hydrochloric acid 
was faster (completed within 1 h), more 
efficient (see Figure 3) and less expensive 
than with [3-glucuronidase/sulfatase. 
The chromatographic system described 
here was originally developed for the 
analysis of methadone in pharmaceutical 
preparations (48). Subsequently, it was rou- 
tinely used in our laboratory for the analysis 
of psychotropic substances in biological 
matrix (e.g., determination of cathinone 
and its metabolites in plasma [49] and urine 
[50] as well as for MDMA and MDA in urine 
[35]). The selectivity of this universal HPLC 
method can easily be optimized for basic 
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analytes of a wide range of polarity (even for zwitter ions) by 
modifying the ratio of acetonitrile-water and the concentration 
of hexylamine. The latter serves as a modifier and masking 
agent for residual silanol groups on the Cls reversed-phase ma- 
terial, resulting in improved peak shape and smaller k' values. 
Figure 3 shows the chromatogram of an urine collected 21.5 h 
after the oral administration of 1.5 mg/kg-body weight MDMA, 
which indicates that even the more polar metabolites, HHMA, 
HMA, and HMMA, are separated and do not interfere with the 
endogenous matrix. 
Peak identification was achieved by comparing retention 
times and DAD-UV spectra of standards. The UV spectrum of 
the methylenedioxy-type amphetamines (MDMA, MDA, etc.) is 
characterized by maxima at 200, 236, and 284 nm, whereas the 
hydroxy/methoxy ring-substituted derivatives (HMMA, HMA, 
etc.) show maxima at 200, 228, and 278 nm. The correct peak 
assignment was confirmed by GC-MS. The low UV cutoff of the 
mobile phase allows the sensitive detection at 200 nm, where 
MDMA and metabolites exhibit their main UV maximum. The 
resulting limit of quantitation (LOQ) of MDMA was 7 ng/mL in 
plasma and urine with a signal-to-noise ratio of greater than 3. 
The LOQ of MDA was 5 ng/mL in plasma and urine. The LOQ 
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Figure 5. Plasma profiles of subjects A and B after an oral dose of 1.5 mg/kg 3,4-methylene- 
dioxymethamphetamine (MDMA). 
of HMA and HMMA in urine was 15 ng/mL. Due to the ex- 
tremely unstable nature of the dihydroxylated metabolite 
HHMA, this MDMA metabolite could not be quantitated but 
only identified in urine. HHA was not detectable by HPLC. 
The interday precision of the MDMA quantitation was 0.9%, 
which was determined with a 1800 ng/mL spiked urine sample 
and showed the excellent reproducibility of the HPLC method 
for the parent compound. For the main metabolite, HMMA, an 
interday precision of 8.9% was calculated. Triplicate analyses 
were performed on three different days during a 2-week period. 
GC-MS analysis 
Extraction and cleanup for GC-MS analysis of urine samples 
were achieved by using the SPE disc technology. The SPEC 
MP1 (Solid Phase Extraction Concentrators, Mixed Phase) 
microcolumns consist of a rigid glass fiber disc coated with 
modified silica. Compared with the classic packed-bed car- 
tridge SPE technique, less sample, solvents, and processing 
time are needed, and cleaner extracts with high analyte 
recovery result (51). The procedure is reproducible, inexpen- 
sive, and allows on-disc derivatization, but cannot be auto- 
mated. To remove the relatively involatile excess of deriva- 
tizing reagent and reaction byproducts, 
which produce high background levels and 
shorten the column life, a wash step is rec- 
ommended (52). 
Figure 4 shows the GC-MS profile of a 
derivatized urine extract before and after 
enzymatic and acidic hydrolysis acquired in 
the full scan mode. By comparing the chro- 
matogram with the HPLC profile of the 
same urine specimen (Figure 3) collected 
21.5 h from subject B after administration 
of 1.5 mg/kg-body weight MDMA, a correla- 
tion can be observed, confirming the cor- 
rect HPLC peak identification. HHA could 
not be identified by HPLC but was detect- 
able in urine by GC-MS. Although the pre- 
sent GC-MS method has only been estab- 
lished for the qualitative profiling of urine, 
it may also be used with slight modifica- 
tions in the SPE procedure for the quanti- 
tative analysis of urine and plasma samples. 
Plasma levels, urinary excretion, and 
metabolism of MDMA 
Figure 5 represents the plasma profiles of 
MDMA and MDA of subject A and B after 
administration of 1.5 mg/kg body weight 
MDMA. MDMA appeared in plasma within 
15 (subject B) and 30 rain (subject A) and 
reached the peak plasma levels of 330.3 
(subject A) and 331.3 ng/mL (subject B) 
after 120 rain. MDA, the only metabolite 
identified in plasma, was first detectable 
after 90 (subject B) and 135 rain (subject A). 
Peak plasma concentrations of 15.3 (sub- 
ject A) and 10.0 ng/mL (subject B) were 
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measured after 380 and 150 min, respectively. Significant 
amounts of MDMA were found 8 h after administration. 
Figure 6 represents the urine excretion profiles of subjects 
A and B after administration of 1.5 mg/kg-body weight MDMA. 
MDMA concentrations ranged from 13.09 to 28.14 IJg/mL in 
the urine of subject A and from 0 to 18.12 IJg/mL in the urine 
of subject B with peak values after 5 and 21.5 h, respectively. Up 
to 24.58 IJg/mL HMMA (subject A) and 35.08 IJg/mL (subject B) 
could be detected between 1.5 and 16 h. The MDA urine con- 
centrations varied from 0.11 to 2.30 IJg/mL (subject A) and 
from 0 to 1.58 1Jg/mL (subject B) with maximum levels 
occurring after 5 and 21.5 h. Concentrations of 0-1.20 IJg/mL 
of HMA, the other minor MDMA metabolite, were measured for 
subject A and 0-2.05 IJg/mL were measured for subject B. The 
highest concentrations appeared between 5.5 and 21.5 h. When 
comparing the urine profiles before and after hydrolysis 
(Figure 3), it is obvious that the metabolites with an open 
methylenedioxy ring (HMMA, HMA, HHMA) are excreted 
mainly as conjugates (glucuronides and/or sulfates). These 
urine data reflect the interindividual differences in the excre- 
tion pattern and that HMMA (as conjugate), and not MDA as 
found earlier (43), is the major urinary metabolite of MDMA. 
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2oe0e  9 
g 
15000 '  
0 
I 0 0 0 0 '  
5 0 0 0 '  
The HMMA peak concentration may even exceed that of the 
parent compound MDMA. The metabolic scheme of MDMA is 
summarized in Figure 1. Our results confirm the findings of an 
uncontrolled study wherein one urine specimen from a fatally 
injured motorcyclist was analyzed by GC-MS (38). Although no 
quantitation was performed, it was suggested that HMMA is the 
major metabolite and HHMA, HMA, and MDA are formed as 
further metabolites. 
The present study has been followed by a trial with six 
patients and slight modifications of the protocol (longer col- 
lection periods). The full pharmacokinetic and statistical data 
evaluation is currently in progress. 
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Figure 6. Urine profiles of subjects A and B after an oral dose of 1.5 mg/kg 3,4-methylene- 
dioxymethamphetamine (MDMA). 
HPLC in combination with automated SPE is the method 
of choice for the pharmacokinetic profiling of MDMA and 
its conjugated and unconjugated metabolites in plasma and 
urine. GC-MS with SPEC-ODD sample preparation is recom- 
mended as the confirmation method. The controlled clinical 
trial with orally administered MDMA has 
shown that the main metabolic pathways of 
MDMA in man are cleavage of the methyl- 
enedioxy bridge, demethylation, and conju- 
gation with HMMA and HHMA as major uri- 
nary metabolites. 
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